Feedback / Questions
AD-214 - AdAlta
https://au.investing.com/news/stock-market-news/adalta-receives-ethics-approval-to-extend-phase-1-clinical-study-for-ibody-ad214-targeting-fibrotic-disease-2904025
Jun 29, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next